Background and aimPancreatic cancer (PC) is one of the most common tumors with a poor prognosis. The current American Joint Committee on Cancer (AJCC) staging system, based on the anatomical features of tumors, is insufficient to predict PC outcomes. The current study is endeavored to identify important prognosis-related genes and build an effective predictive model.MethodsMultiple public datasets were used to identify differentially expressed genes (DEGs) and survival-related genes (SRGs). Bioinformatics analysis of DEGs was used to identify the main biological processes and pathways involved in PC. A risk score based on SRGs was computed through a univariate Cox regression analysis. The performance of the risk score in predicting PC prognosis was evaluated with survival analysis, Harrell’s concordance index (C-index), area under the curve (AUC), and calibration plots. A predictive nomogram was built through integrating the risk score with clinicopathological information.ResultsA total of 945 DEGs were identified in five Gene Expression Omnibus datasets, and four SRGs (LYRM1, KNTC1, IGF2BP2, and CDC6) were significantly associated with PC progression and prognosis in four datasets. The risk score showed relatively good performance in predicting prognosis in multiple datasets. The predictive nomogram had greater C-index and AUC values, compared with those of the AJCC stage and risk score.ConclusionThis study identified four new biomarkers that are significantly associated with the carcinogenesis, progression, and prognosis of PC, which may be helpful in studying the underlying mechanism of PC carcinogenesis. The predictive nomogram showed robust performance in predicting PC prognosis. Therefore, the current model may provide an effective and reliable guide for prognosis assessment and treatment decision-making in the clinic.
Achieving high detection accuracy of pavement cracks with complex textures under different lighting conditions is still challenging. In this context, an encoder-decoder network-based architecture named CrackResAttentionNet was proposed in this study, and the position attention module and channel attention module were connected after each encoder to summarize remote contextual information. The experiment results demonstrated that, compared with other popular models (ENet, ExFuse, FCN, LinkNet, SegNet, and UNet), for the public dataset, CrackResAttentionNet with BCE loss function and PRelu activation function achieved the best performance in terms of precision (89.40), mean IoU (71.51), recall (81.09), and F1 (85.04). Meanwhile, for a self-developed dataset (Yantai dataset), CrackResAttentionNet with BCE loss function and PRelu activation function also had better performance in terms of precision (96.17), mean IoU (83.69), recall (93.44), and F1 (94.79). In particular, for the public dataset, the precision of BCE loss and PRelu activation function was improved by 3.21. For the Yantai dataset, the results indicated that the precision was improved by 0.99, the mean IoU was increased by 0.74, the recall was increased by 1.1, and the F1 for BCE loss and PRelu activation function was increased by 1.24.
This study demonstrated that the long-term outcomes of the patients with CL-HCC in these two groups were not significantly different. For short-term outcomes, CH resulted in a lower rate of postoperative liver failure, while MH resulted in a lower incidence of biliary fistula. Nonetheless, compared with MH, CH provided CL-HCC patients with greater future remnant liver volume without an increased risk of early intra-hepatic recurrence. More multi-centre, randomized controlled trials comparing the therapeutic efficacy of CH and MH are urgently warranted.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.